Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CCA tRNA nucleotidyltransferase 1, mitochondrial (TRNT1) is an essential nucleotidyltransferase enzyme that catalyzes the addition and repair of the conserved CCA sequence at the 3' end of tRNA molecules, a modification required for tRNA aminoacylation and subsequent protein translation. It is a mitochondrial enzyme encoded by the nuclear genome, playing a central role in both tRNA maturation and tRNA quality control by distinguishing stable tRNAs (adding CCA) from unstable or defective tRNAs (adding CCACCA, leading to degradation). Mutations in TRNT1 cause inherited diseases such as sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay, highlighting its crucial role in cellular and mitochondrial function[1][2][4][7]. No approved drugs directly target TRNT1, reflecting its essential housekeeping role and the likely toxicity of its inhibition.
Drugs targeting this enzyme would theoretically inhibit or modify the CCA-adding function, interfering with tRNA maturation and mitochondrial protein synthesis (no therapeutic drugs currently known)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CCA tRNA nucleotidyltransferase 1, mitochondrial (TRNT1).